Durable Response Rate
MZL Efficacy Data: Overall Response Rates | IMBRUVICA® | HCP
ORR (Objective Response Rate) and related statistics – Part 1
Confirmed ORR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Efficacy Data: Overall Response Rate | VITRAKVI® (larotrectinib)
Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
Durable Response Rate
Response Rates for Waldenström Macroglobulinemia Improve With Use of New First-Line, Better-Tolerated Treatments - U.S. Medicine
Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients | PLOS ONE
Efficacy endpoints in Oncology
Confirmed ORR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Durable Responses Are Observed With Cemiplimab in mBCC
The overall response rate | Download Table
Forest plot of the comparison of overall response rate (ORR).
Durable Response Rate
Overall response rate | Download Table
ORR (Objective Response Rate) and related statistics – Part 1
Overall response rate | Download Table
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology
Visualization of efficacy endpoints in oncology clinical trials
Pecoma Clinical Trial Efficacy Data | FYARRO | HCP Site
